UCP (Ultrasound Cyclo Plasty) in the Treatment of Chinese Patients With Primary Open-angle Glaucoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-12

Study Completion Date

2020-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Traditional ciliary body photocoagulation treatment uses the photocoagulation of long-wavelength laser to destroy the ciliary body tissue that can produce aqueous humor. Therefore, it is a kind of palliative treatment which has proved efficacy but causes great pain to patients. The "ultrasonic glaucoma treatment instrument" produced by French EYE TECH CARE company is referred to as EyeOP1. It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

UCP Glaucoma Treatment for Primary Glaucoma in China

NCT04145830

Glaucoma Treatment Using Focused Ultrasound

COMPLETED NA

Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients

NCT02789293

Glaucoma

COMPLETED NA

Cyclophotocoagulation in Primary Open Angle Glaucoma

NCT04430296

Primary Open Angle Glaucoma

UNKNOWN NA

Comparison of Cytokines Profile in Aqueous Humor and Tear Before and After UCP Treatment

NCT06243497

Glaucoma Ultrasound Cyclo Plasty Aqueous Humor +2 more

RECRUITING

Circular Cyclocoagulation Using HIFU With EYEOP1 Device in Glaucoma Patients

NCT01791673

Glaucoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Efficacy: 1. Main objective: (1)Assess the decrease in postoperative intraocular pressure from baseline and evaluate the final results (the percentage of patients whose conditions have significant improved and the variation of the percentage of median intraocular pressure. (2)Assess the amount of medication after surgery.
2. Secondary goals:(1) Compare median intraocular pressure with baseline at each postoperative follow-up and access the variation of median intraocular pressure from baseline at each postoperative follow-up. (2) Count the number of intraocular pressure lowering drugs at each postoperative follow-up.

b.Safety: Investigate the incidence of all device-related(or procedure-related) adverse events during the study (intraoperative and postoperative follow-up).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma Glaucoma, Primary Open Angle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ultrasound cyclo plasty(UCP)

Ultrasound cyclo plasty treatment for primary open-angle glaucoma patients.

Group Type EXPERIMENTAL

ultrasound cyclo plasty

Intervention Type PROCEDURE

The "ultrasonic glaucoma treatment instrument" produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ultrasound cyclo plasty

The "ultrasonic glaucoma treatment instrument" produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

UCP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The target eye was diagnosed as primary open-angle glaucoma; diagnostic criteria: IOP(intraocular pressure)≥ 21, open angle, typical glaucoma visual field and optic disc damage;
* Patients treated with glaucoma medications cannot control intraocular pressure effectively;
* Patients with 21mmHg ≤ IOP ≤ 30mmHg;
* VA(visual acuity)≥HM(hand motions);
* Patients that have failed conventional glaucoma surgery (trabeculectomy) or are not suitable for surgery;
* Patients who have not received intraocular surgery or laser treatment 90 days before receiving HIFU;
* Aged from 18 to 90 years old;
* Sign informed consent and be willing to provide visit data;

Exclusion Criteria

* Either eye have any infections two weeks before the surgery;
* The target eye has history of ciliary surgery, intraocular or retrobulbar tumor;
* The target eye is neovascular glaucoma;
* The target eye is aphakic eye;
* Anterior anatomical abnormalities cause scleral expansion or ciliary body ectopic;
* Non-glaucoma intraocular diseases that affect intraocular pressure;
* Within 30 days, the patient participated in or was simultaneously included in other clinical trials;
* Patients during pregnancy or lactation;
* Any systemic disease that may affect patient follow-up.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes